Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis...
Q1 2026
May 12, 2026
FY 2025
Mar 2, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 11, 2025